A Study to Assess the Reduction of Human Papillomavirus (HPV) Viral Infectivity and Transmission in HPV-Positive Women After Vaccination With 9vHPV (RIFT-HPV)

Inclusion Criteria: * Women. * Aged 18 years or older for RIFT-HPV Cohort 1 and 2, attending a routine cervical cancer screening visit or gynaecological visit. * Positive for HPV16, 18 or double-positive for 16 and 18 and negative for the rest of high-risk HPV types in a cervical sample. * Recently diagnosed for their HPV-positivity (within the last 10 months). * Meet one of the following criteria: have no apparent cervical lesion (Cohort 1). have a CIN1/2 lesion which is eligible for conservative treatment (cohort 1). have HPV 16 and/or HPV 18 positive anal test with non-apparent anal lesions or with anal lesions eligible for conservative treatment (Cohort 2). have HPV 16 and/or HPV 18 positive cervical test with vulvar premalignant lesion or condylomas, associated to HPV infection (Cohort 2). Exclusion Criteria: * Presence of any cervical lesion that requires clinical intervention within 7 months that could significantly affect cervical epithelia (and therefore, HPV viral production), such as cervical conization. * History of severe allergic reaction (e.g., swelling of the mouth and throat, difficulty breathing, hypotension, or shock) that required medical intervention. * History of allergy to any vaccine component, including aluminum, yeast, or BENZONASETM (nuclease, Nicomedia). * History of thrombocytopenia or any coagulation disorder that would contraindicate intramuscular injection of study vaccine. * History of splenectomy. * History of ano-genital cancer or HPV-related head and neck cancer. * Pregnancy at the time of signing informed consent or planning to become pregnant within the full duration of the study.